Q1 2025 Poly Medicure Ltd Earnings Call Transcript
Key Points
- Revenue increased by 20% from Q1 FY24 to Q1 FY25, reaching 385 crores.
- EBITDA margin improved by 20%, from 87 crores to 104 crores.
- PAT margin rose by 18%, from 62.7 crores to 74 crores.
- Capacity expansion is on track, with plans to increase from 1.5 billion units to 1.7-1.8 billion units by year-end.
- Renal business saw a significant growth of over 40% in Q1 FY25.
- Domestic business growth was only 6-7%, impacted by the end of government orders for vaccination program syringes.
- PLI scheme has not been favorable for the med-tech industry, with only 85 crores allocated in the current budget.
- China plant is underperforming due to high cost structure and may be shut down in the next 18-24 months.
- Logistical challenges such as container shortages and increased sea freight costs are impacting short-term business.
- CapEx requirements are substantial, with plans to spend around 600 crores per year for the next three years.
(Operator Instructions)
Thank you, Angelie. Good afternoon, everyone. On behalf of ICICI Securities, I would like to welcome you all on Q1 FY25 earnings call of Poly Medicure Limited.
Today on this call, we have the senior management of the company represented by Mr. Himanshu Baid,Managing Director; Mr. Naresh Vijayvergiya, CFO; and Mr. Avinash Chandra, Company Secretary. I would like to thank the management of PolyMedica's for giving us this opportunity to host this call. And with this, I will hand over the call to the management. Over to you, sir.
Thank you, Alicia, and thank you for all of us in this call and good afternoon, everybody and our strategy to talk to you again about the progress of the company for the previous quarter. I will take you through the earnings of Q1 FY 25, the revenue of the Company and compare from Q1 of FY 24 to FY 25 increase from 20 crores to 385 crores, roughly almost increase
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
